Leerink Partners Starts Evommune Inc (EVMN) at Outperform

Leerink Partners analyst Thomas Smith initiates coverage on Evommune Inc (NYSE: EVMN) with a Outperform rating and a price target of $42.00.

The analyst comments "Overall, we believe EVO756 and EVO301 both offer pipeline-in-a-product potential to address multiple sizable chronic inflammatory diseases. With upcoming potentially value-inflecting readouts, growing strategic interest in novel therapeutic targets, and sufficient capital to reach these key milestones, we believe EVMN is entering a data catalyst-rich 2026 with significant upside potential and the opportunity to be an important player in immuno-dermatology and broader inflammatory disease space."

For an analyst ratings summary and ratings history on Evommune Inc click here. For more ratings news on Evommune Inc click here.

Shares of Evommune Inc closed at $20.71 yesterday.

You May Also Be Interested In

• Stifel Starts Arrowhead Pharma (ARWR) at Buy
• Penguin Solutions plans $650M convertible notes offering due 2031
• Entrée Resources names Chris Adams as new CEO effective July 17